EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease

Alparslan Demiray, Ramazan Ozan, Salih Güntuğ Özaytürk, Hakan İmamoğlu, Gökmen Zararsız, Murat Hayri Sipahioğlu, Bülent Tokgöz, Deniz Elçik, İsmail Koçyiğit

Cardiorenal Medicine · 2024

DOI: 10.1159/000538098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiorenal Medicine, 2024. Verfasst von Alparslan Demiray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Internal Medicine, Erciyes University, Kayseri, Turkey. Hauptthemen laut MEDLINE: Tolvaptan, Polycystic Kidney, Autosomal Dominant, Antidiuretic Hormone Receptor Antagonists, Glomerular Filtration Rate. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Cardiovascular diseases constitute a significant cause of morbidity and mortality in individuals with autosomal dominant polycystic kidney disease (ADPKD). This study aims to assess the long-term effects of tolvaptan on the kidneys and heart in rapidly progressing ADPKD.

Methods

Among 354 patients diagnosed with ADPKD, 58 meeting the eligibility criteria for tolvaptan were included in the study. The study comprised two groups with similar demographic and clinical characteristics: 29 patients receiving tolvaptan treatment and 29 in the control group. Several included genetic analysis, magnetic resonance imaging (MRI), and echocardiography. Clinical and cardiac changes were recorded in both groups after a three year follow-up.

Results

Tolvaptan treatment demonstrated a significant reduction in the rate of eGFR decline compared to the control group. Furthermore, it was observed that tolvaptan could prevent the development of cardiac arrhythmias by inhibiting an increase in QTc interval and heart rate.

Conclusion

These findings suggest that, in addition to slowing kidney progression in ADPKD management, tolvaptan may potentially benefit in preventing cardiac complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanPolycystic Kidney, Autosomal DominantAntidiuretic Hormone Receptor AntagonistsGlomerular Filtration RateHumansMaleFemaleAdultMiddle AgedDisease ProgressionMagnetic Resonance ImagingEchocardiographyKidneyCardiovascular DiseasesFollow-Up Studies

Stichwörter der Autor:innen

Autosomal dominant polycystic kidney diseaseCardiac effectsKidney progressionQTc intervalTolvaptan

Substanzen

TolvaptanAntidiuretic Hormone Receptor Antagonists

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Internal Medicine, Erciyes University, Kayseri, Turkey.
  • Faculty of Medicine, Department of Cardiology, Erciyes University, Kayseri, Turkey.
  • Faculty of Medicine, Department of Radiology, Erciyes University, Kayseri, Turkey.
  • Faculty of Medicine, Department of Biostatistics, Erciyes University, Kayseri, Turkey.
  • Faculty of Medicine, Department of Nephrology, Erciyes University, Kayseri, Turkey.

Zitieren

APA

Demiray, A., Ozan, R., Özaytürk, S. G., İmamoğlu, H., Zararsız, G., Sipahioğlu, M. H., Tokgöz, B., Elçik, D., & Koçyiğit, İ. (2024). Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease. Cardiorenal Medicine. https://doi.org/10.1159/000538098

Vancouver

Demiray A, Ozan R, Özaytürk SG, İmamoğlu H, Zararsız G, Sipahioğlu MH, et al. Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease. Cardiorenal Medicine. 2024. doi:10.1159/000538098

BibTeX
@article{Demiray2024,
  author = {Demiray, Alparslan and Ozan, Ramazan and Özaytürk, Salih Güntuğ and İmamoğlu, Hakan and Zararsız, Gökmen and Sipahioğlu, Murat Hayri and Tokgöz, Bülent and Elçik, Deniz and Koçyiğit, İsmail},
  title = {Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease},
  journal = {Cardiorenal Medicine},
  year = {2024},
  doi = {10.1159/000538098}
}
Kostenlos starten →